biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs

Bullboard Posts

Comment by BearDownAZon Jun 13, 2017 10:13am

131 Views

Post# 26356118

RE:LSD presentation results

Great questions Robert. I too am anxious to hear answers to these. Just a reminder that biOasis is attending the Blood Brain Barrier conference in Boston today and tomorrow. I'm not sure who from biOasis is attending though. Also, Mark Day will present at (RH also attending) the the Global Chinese Financial Forum (GCFF)/Shanghai Conference on June 22, 2017. Hopefully after these events wrap up we get our long overdue corporate update.

BearDownAZ

Bullboard Posts

Investor’s corner: Solving chronic pain in dogs – A significant market opportunity